Matthew P. Conomos

Matthew P. Conomos

Auto-generated profile, based on publicly available information

Matthew P. Conomos

University of Washington

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2021 in Nature
Verified
Journal Article
Open access
PDF file
DTDaniel Taliun
Daniel Taliun
DHDaniel N Harris
Daniel N Harris
MKMichael D Kessler
Michael D Kessler
JCJedidiah Carlson
Jedidiah Carlson
ZSZachary A Szpiech
Zachary A Szpiech
GAGonçalo R Abecasis
Gonçalo R Abecasis
The Trans-Omics for Precision Medicine (TOPMed) programme seeks to elucidate the genetic architecture and biology of heart, lung, blood and sleep disorders, with the ultimate goal of improving diagnosis, treatment and prevention of these diseases. The initial phases of the programme focused on whole-genome sequencing of individuals with rich phenotypic data and diverse backgrounds. Here we describe the TOPMed goals and design as well as the available resources and early insights obtained from the sequence data. The resources include a variant browser, a genotype imputation server, and genomic and phenotypic data that are available through dbGaP (Database of Genotypes and Phenotypes)1. In the first 53,831 TOPMed samples, we detected more than 400 million single-nucleotide and insertion or deletion variants after alignment with the reference genome. Additional previously undescribed variants were detected through assembly of unmapped reads and customized analysis in highly variable loci. Among the more than 400 million detected variants, 97% have frequencies of less than 1% and 46% are singletons that are present in only one individual (53% among unrelated individuals). These rare variants provide insights into mutational processes and recent human evolutionary history. The extensive catalogue of genetic variation in TOPMed studies provides unique opportunities for exploring the contributions of rare and noncoding sequence variants to phenotypic variation. Furthermore, combining TOPMed haplotypes with modern imputation methods improves the power and reach of genome-wide association studies to include variants down to a frequency of approximately 0.01%.

19 June 2019 in Nature
Verified
Journal Article
Closed access
PDF file
GWGenevieve L. Wojcik
Genevieve L. Wojcik
MGMariaelisa Graff
Mariaelisa Graff
KNKatherine K. Nishimura
Katherine K. Nishimura
RTRan Tao
Ran Tao
JHJeffrey Haessler
Jeffrey Haessler
CCChristopher S. Carlson
Christopher S. Carlson

6 May 2012 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CLCathy C Laurie
Cathy C Laurie
CLCecelia A Laurie
Cecelia A Laurie
KRKenneth Rice
Kenneth Rice
KDKimberly F Doheny
Kimberly F Doheny
LZLeila R Zelnick
Leila R Zelnick
BWBruce S Weir
Bruce S Weir
Cathy Laurie and colleagues detect mosaicism for large chromosomal abnormalities in peripheral blood in a subset of healthy individuals. They show that the frequency of such events increases with age and is associated with elevated risk of developing a subsequent hematological cancer. We detected clonal mosaicism for large chromosomal anomalies (duplications, deletions and uniparental disomy) using SNP microarray data from over 50,000 subjects recruited for genome-wide association studies. This detection method requires a relatively high frequency of cells with the same abnormal karyotype (>5–10%; presumably of clonal origin) in the presence of normal cells. The frequency of detectable clonal mosaicism in peripheral blood is low (<0.5%) from birth until 50 years of age, after which it rapidly rises to 2–3% in the elderly. Many of the mosaic anomalies are characteristic of those found in hematological cancers and identify common deleted regions with genes previously associated with these cancers. Although only 3% of subjects with detectable clonal mosaicism had any record of hematological cancer before DNA sampling, those without a previous diagnosis have an estimated tenfold higher risk of a subsequent hematological cancer (95% confidence interval = 6–18).

22 July 2019 in Bioinformatics
Verified
Journal Article
Closed access
PDF file
SGStephanie M Gogarten
Stephanie M Gogarten
TSTamar Sofer
Tamar Sofer
HCHan Chen
Han Chen
CYChaoyu Yu
Chaoyu Yu
JBJennifer A Brody
Jennifer A Brody
MCMatthew P Conomos
Matthew P Conomos
The Genomic Data Storage (GDS) format provides efficient storage and retrieval of genotypes measured by microarrays and sequencing. We developed GENESIS to perform various single- and aggregate-variant association tests using genotype data stored in GDS format. GENESIS implements highly flexible mixed models, allowing for different link functions, multiple variance components and phenotypic heteroskedasticity. GENESIS integrates cohesively with other R/Bioconductor packages to build a complete genomic analysis workflow entirely within the R environment. https://bioconductor.org/packages/GENESIS; vignettes included. Supplementary data are available at Bioinformatics online.

1 January 2016 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
MCMatthew P. Conomos
Matthew P. Conomos
ARAlexander P. Reiner
Alexander P. Reiner
BWBruce S. Weir
Bruce S. Weir
TTTimothy A. Thornton
Timothy A. Thornton

23 March 2015 in Genetic Epidemiology
Verified
Journal Article
Closed access
PDF file
MCMatthew P. Conomos
Matthew P. Conomos
MMMichael B. Miller
Michael B. Miller
TTTimothy A. Thornton
Timothy A. Thornton